ORIC
Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
CUSIP: 68622P109HealthcareUS3 holders
Recent Activity
2026Q2
2 sells
-377.6K shares(-39.3%)
-377.6K shares(-39.3%)
-697.8K shares(-12.0%)
-697.8K shares(-12.0%)
2026Q1
2 sells
-103.3K shares(-9.7%)
-103.3K shares(-9.7%)
-748.2K shares(-11.4%)
-748.2K shares(-11.4%)
Loading more activity...